People
The Cambridge, Mass.-based company announced that industry veteran Grant Bogle has taken over as president and CEO.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
The Trump White House removed Bright from his position at BARDA and reassigned him to a narrower role at the National Institutes of Health.
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Tadataka “Tachi” Yamada, a former GlaxoSmithKline and Takeda Pharmaceutical executive, early gene therapy backer, and philanthropist, passed away on Wednesday of natural causes at the age of 76.
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.
“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
PRESS RELEASES